Computational Design of Cell-Penetrating Peptides to Deliver the Anti-Cancer Protein Endostatin

Computer modeling identified four cell-penetrating peptides — Cyt c-ss-MAP, TP-biot1, MPGα, and DPV1047 — as optimal candidates for delivering the anti-cancer protein endostatin into cells.

Zamani, Mozhdeh et al.·Current computer-aided drug design·2024·Preliminary Evidencein vitro
RPEP-09623In vitroPreliminary Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in vitro
Evidence
Preliminary Evidence
Sample
N=not applicable
Participants
Computational analysis of CPP-endostatin binding interactions

What This Study Found

Four CPPs (Cyt c-ss-MAP, TP-biot1, MPGα, DPV1047) were computationally predicted to form stable, non-antigenic fusions with endostatin that could improve its delivery and overcome its clinical limitations of poor stability and low half-life.

Key Numbers

Multiple CPP candidates were computationally evaluated for endostatin binding and delivery characteristics.

How They Did This

Computational study using multiple bioinformatics tools: ProtParam for stability/hydrophobicity, VaxiJen for antigenicity prediction, DeepLoc-1.0 for subcellular localization, I-TASSER for 3D structure modeling, and PROCHECK/ERRAT/Verify3D/ProSA-Web for model validation.

Why This Research Matters

Endostatin showed promise in early cancer research but failed clinically due to instability. If cell-penetrating peptides can solve this delivery problem, it could revive endostatin as an anti-cancer therapy and demonstrate a broader approach for rescuing unstable protein drugs.

The Bigger Picture

Many promising protein drugs fail because they are unstable or cannot reach their targets inside cells. Cell-penetrating peptides offer a general solution — they can carry large cargo across cell membranes. This study applies computational screening to match CPPs with specific therapeutic proteins, a strategy that could accelerate peptide-based drug delivery design.

What This Study Doesn't Tell Us

Entirely computational — no experimental validation in cells, animals, or humans. Computational predictions do not always match real-world behavior. CPP-fusion proteins may have unexpected toxicity, immunogenicity, or stability issues in biological systems. The transition from in silico to in vivo often reveals unforeseen challenges.

Questions This Raises

  • ?Will these CPP-endostatin fusions actually penetrate cells and maintain anti-angiogenic activity in laboratory tests?
  • ?Could these same CPPs be used to deliver other unstable therapeutic proteins beyond endostatin?
  • ?What are the safety profiles of these specific CPPs when used as delivery vehicles in animal models?

Trust & Context

Key Stat:
4 CPPs identified as computationally optimal carriers for endostatin delivery, with high stability and no predicted immunogenicity
Evidence Grade:
Preliminary evidence: purely computational study with no experimental validation. Results are theoretical predictions that require laboratory and eventually clinical testing.
Study Age:
Published in 2024. Uses current computational tools for peptide fusion design.
Original Title:
Application of Cell Penetrating Peptides for Intracellular Delivery of Endostatin: A Computational Approach.
Published In:
Current computer-aided drug design, 20(3), 208-223 (2024)
Database ID:
RPEP-09623

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What are cell-penetrating peptides?

Cell-penetrating peptides (CPPs) are short chains of amino acids that can cross cell membranes and carry other molecules inside. They act like molecular delivery trucks, helping therapeutic proteins reach their targets inside cells.

Why did endostatin fail as a cancer drug?

Endostatin showed promise in blocking tumor blood vessel growth, but it breaks down too quickly in the body and has difficulty reaching cancer cells. CPP fusions could solve both problems by protecting endostatin and helping it enter cells.

Read More on RethinkPeptides

Cite This Study

RPEP-09623·https://rethinkpeptides.com/research/RPEP-09623

APA

Zamani, Mozhdeh; Nezafat, Navid; Mokarram, Pooneh; Kadkhodaei, Behnam. (2024). Application of Cell Penetrating Peptides for Intracellular Delivery of Endostatin: A Computational Approach.. Current computer-aided drug design, 20(3), 208-223. https://doi.org/10.2174/1573409919666230426093230

MLA

Zamani, Mozhdeh, et al. "Application of Cell Penetrating Peptides for Intracellular Delivery of Endostatin: A Computational Approach.." Current computer-aided drug design, 2024. https://doi.org/10.2174/1573409919666230426093230

RethinkPeptides

RethinkPeptides Research Database. "Application of Cell Penetrating Peptides for Intracellular D..." RPEP-09623. Retrieved from https://rethinkpeptides.com/research/zamani-2024-application-of-cell-penetrating

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.